» Articles » PMID: 22245890

The Impact of Organ Dysfunction in Cirrhosis: Survival at a Cost?

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2012 Jan 17
PMID 22245890
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: The incidence of cirrhosis and subsequent development of organ dysfunction (OD) requiring intensive care unit (ICU) support is rising. Historically, critically ill cirrhotics are perceived as having poor prognosis and substantial cost of care.

Methods: The aim was to prospectively analyse resource utilisation and cost of a large cohort of patients (n=660) admitted to a Liver ICU from 2000 to 2007 with cirrhosis and OD. Child Pugh, MELD, SOFA, APACHE II, and organ support requirements were collected. The Therapeutic Intervention Scoring System (TISS) score, a validated tool for estimating cost in ICU, was calculated daily. Logistic regression was used to determine independent predictors of increased cost.

Results: Alcohol was the most common etiology (47%) and variceal bleeding (VB) the most common reason for admission (35%). Invasive ventilatory support was required in 74% of cases, vasopressors in 49%, and 50% required renal replacement therapy. Forty-nine per cent of non-transplanted patients survived to ICU discharge. Median TISS score and ICU cost per patient were 261 and €14,139, respectively. VB patients had the highest survival rates (53% vs. 24%; p<0.001) and lower associated cost. A combination of VB (OR 0.48), need for ventilation (OR 2.81), low PO(2)/FiO(2) on admission (OR 0.97), and lactate (OR 0.93) improved cost prediction on multivariate analysis (AUROC 0.7; p<0.001) but organ failure scores per se were poor predictors of cost.

Conclusions: Patients with cirrhosis and OD result in considerable resource expenditure but have acceptable hospital survival. Further health economic assessment and outcome prediction tools are required to appropriately target resource utilisation.

Citing Articles

Analysis of the prognostic efficacy of syndecan-1 for patients with ACLF and its functional role in liver regeneration.

He Y, Zhang X, Yao Y, Li J, Fu S, Feng Y BMC Med. 2025; 23(1):104.

PMID: 39985044 PMC: 11846419. DOI: 10.1186/s12916-025-03931-4.


The patient with cirrhosis in the intensive care unit and the management of acute-on-chronic liver failure.

Passi N, McPhail M J Intensive Care Soc. 2023; 23(1):78-86.

PMID: 37593538 PMC: 10427846. DOI: 10.1177/1751143720978849.


Neurological Wilson's Disease Signs-Hepatic Encephalopathy or Copper Toxicosis?.

Jopowicz A, Tarnacka B Diagnostics (Basel). 2023; 13(5).

PMID: 36900037 PMC: 10001333. DOI: 10.3390/diagnostics13050893.


Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus.

Wu D, Rao Q, Xie Z, Zhu X, Che Y, Wu J Clin Mol Hepatol. 2022; 28(4):912-925.

PMID: 35896280 PMC: 9597222. DOI: 10.3350/cmh.2022.0121.


Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Marjot T, Eberhardt C, Boettler T, Belli L, Berenguer M, Buti M J Hepatol. 2022; 77(4):1161-1197.

PMID: 35868584 PMC: 9296253. DOI: 10.1016/j.jhep.2022.07.008.